|Combined optical frequency-domain imaging and near-infrared fluorescence image of the inner surface of a rabbit artery shows an implanted arterial stent (blue) and fibrin deposits (red-yellow). By revealing both structural and molecular detail, OFDI-NIRF may improve diagnosis of coronary artery disease and help evaluate stent healing. (Image courtesy of Massachusetts General Hospital)|
Researchers at Massachusetts General Hospital (MGH; Boston, MA) have developed an intra-arterial catheter that mixes optical frequency-domain imaging (OFDI) and near-infrared fluorescence (NIRF) imaging to obtain simultaneous structural and molecular images of internal arterial surfaces.
Having performed their tests in rabbits, their device could reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could provide a better diagnostic tool for assessing vascular pathology, such as the risk of heart attacks or the formation of clots in arterial stents, says Gary Tearney, MD, Ph.D., of the Wellman Center for Photomedicine and the MGH Pathology Department and study co-author.
Developed at the Wellman Center, OFDI utilizes a fiber-optic probe with a constantly rotating laser tip to create detailed molecular images of interior surfaces such as arterial walls. While OFDI can be used to guide procedures like coronary artery angioplasty and to confirm the correct positioning of metal stents inserted to keep cleared arteries open, its ability to determine important details of stent healing is limited. Properly healed stents become covered with endothelium, the same tissue that normally coats the arterial surface; but stents can become coated with the clot-inducing protein fibrin, which may put patients at risk for stent thrombosis—a clot that blocks bloodflow through the stent—and OFDI cannot determine the molecular composition of tissue covering a stent.
Intravascular NIRF technology was developed in the MGH Cardiovascular Research Center (CVRC), in collaboration with colleagues at the Technical University of Munich, and uses special imaging agents to detect cells and molecules involved in vascular processes like clotting and inflammation. Recognizing the potential advantage of combining both technologies, the Wellman researchers worked with the MGH-CVRC team, led by Farouc Jaffer, MD, Ph.D., of the MGH Heart Center to develop an integrated OFDI-NIRF imaging system incorporated in the same intravascular probe used for OFDI alone.
The team first confirmed that the system could provide detailed structural images of a stent implanted in a cadaveric human coronary artery and could accurately identify the presence of fibrin on the stent. In a series of experiments in living rabbits, the OFDI-NIRF system was able to detect fibrin on implanted stents—including areas where it was not detected by OFDI alone—and to identify the presence of both atherosclerotic plaques and enzymatic activity associated with inflammation and plaque rupture. The enzyme signal detected by NIRF was not uniform throughout the imaged plaques, indicating biological differences that could be relevant to prognosis and treatment planning.
The reseachers are still unable to predict which patients may develop stent thrombosis, but integrated OFDI-NIRF can assess many key factors linked to the risk of clot formation, says Jaffer, co-senior author of the study. "If OFDI-NIRF is validated in clinical studies, patients at risk for stent thrombosis could undergo a 'stent check-up' to determine how well the stent is healing. Patients with unhealed stents could be advised to take or continue taking specific anti-clotting medications. Patients with well-healed stents, on the other hand, could potentially discontinue anti-clotting medications, which can cause excess bleeding," he says. Clinical adoption of the integrated technology will require FDA approval of the molecular contrast agents used in NIRF.
Grants from the National Institutes of Health, the Center for Integration of Medicine and Innovative Technology, the American Heart Association, Howard Hughes Medical Institute, and the CardioVascular Research Foundation supported the team's work, and MGH has filed patent applications on the combined OFDI and NIRF technology.
The study has been published online ahead of print in Nature Medicine. For more information, please visit http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.2555.html.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!